Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 10Unknown 4Terminated 4Active not recruiting 2Recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2Thoracic 1Sarcoma 1Head & Neck 1Gynecologic 1Genitourinary 1Dermatologic 1CNS 1Breast 1

Conditions

Pancreatic Neoplasms 42Urinary Bladder Neoplasms 18Carcinoma, Non-Small-Cell Lung 18Ovarian Neoplasms 11Triple Negative Breast Neoplasms 10Neoplasm Metastasis 10Nasopharyngeal Carcinoma 10Breast Neoplasms 10Lymphoma, Large B-Cell, Diffuse 9Fallopian Tube Neoplasms 9Lung Neoplasms 8Carcinoma, Transitional Cell 8Biliary Tract Neoplasms 7Recurrence 6Gallbladder Neoplasms 6Neoplasms 5Cholangiocarcinoma 5Non-Muscle Invasive Bladder Neoplasms 4Colorectal Neoplasms 4Urothelial Cancer 3Stomach Neoplasms 3Melanoma 3Lymphoma, Non-Hodgkin 3Lymphoma 3Carcinoma 3Uterine Cervical Neoplasms 2Urethral Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Pancreatic Adenocarcinoma 2Non Small Cell Lung Carcinoma NSCLC 2

Interventions

Oxaliplatin 14Cetuximab 11Leucovorin 9Fluorouracil 9Magnetic Resonance Spectroscopy 8Nivolumab 7pembrolizumab 6Capecitabine 6encorafenib 5Irinotecan 5Bevacizumab 5dehydroftorafur 4Specimen Handling 4adagrasib 3Immunoglobulin G 3Disulfides 3Biopsy 3selpercatinib 2durvalumab 2cemiplimab 2X-Rays 2Watchful Waiting 2Standard of Care 2Radiotherapy 2Panitumumab 2Observation 2Ipilimumab 2Injections 2Gemcitabine 2Folfox protocol 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Active not recruiting × Colonic Neoplasms × Gemcitabine × Clear all
NCT06607185 2026-05-26

A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors

Eli Lilly and Company

Phase 1 Active not recruiting
750 enrolled
GastrointestinalGynecologicThoracic

Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Esophageal Neoplasms, Lung Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma

NCT04521686 2026-04-22

Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations

Eli Lilly and Company

Phase 1 Active not recruiting
200 enrolled
BreastCNSDermatologicGastrointestinalGenitourinaryHead & NeckSarcoma

Breast Neoplasms, Chondrosarcoma, Colonic Neoplasms, Glioblastoma, Glioma, Melanoma, Prostatic Neoplasms, Thyroid Neoplasms, Central Nervous System Neoplasms, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡